Oxcarbazepine (All indications)

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9039
R30846		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.86 [0.03;115.45] C
excluded (control group) 		0/4   0/7 0 4
ref
S9040
R30856		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 6.14 [0.10;363.16] C 0/4   0/22 0 4
ref
S9041
R30859		 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 0.79 [0.51;1.22]
excluded (control group) 		56/1,109   129/2,682 185 1,109
ref
S9043
R30873		 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.11 [0.85;1.44] 56/1,109   53,634/1,440,631 53,690 1,109
ref
Total 2 studies 1.12 [0.86;1.45] 53,690 1,113
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 1 6.14[0.10; 363.16]040%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019Cohen, 2019 2 1.11[0.85; 1.44]53,6901,109100%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.12[0.86; 1.45]53,6901,1130.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.12[0.86; 1.45]53,6901,1130%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.11[0.85; 1.44]53,6901,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 unexposed, sickunexposed, sick 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 Tags Adjustment   - No  - No 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1   - Yes  - Yes 1.11[0.85; 1.44]53,6901,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 All studiesAll studies 1.12[0.86; 1.45]53,6901,1130%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9041, 9039

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.11[0.85; 1.44]53,6901,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 unexposed, sick controlsunexposed, sick controls 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.80[0.52; 1.23]1851,1130%NAAydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 20.510.01.0